Impact of regulatory issues on drug development for the CNS

被引：0
|
作者：
Kuruma, I
机构：
来源：
PRECLINICAL AND CLINICAL STRATEGIES FOR THE TREATMENT OF NEURODEGENERATIVE, CEREBROVASCULAR AND MENTAL DISORDERS | 1996年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：281 / 282
页数：2
相关论文
共 50 条
  • [41] Guest editor's note: Practical and regulatory issues on new drug, new dosage form, and generic Drug Development
    hu O.Y.-P.
    Chow S.-C.
    Drug information journal : DIJ / Drug Information Association, 1997, 31 (4): : 1145 - 1147
  • [42] The Impact of Regulatory Reforms in China on Drug Lag: The Role of Clinical Development Strategies
    Han, Yue
    Jiang, Rong
    Li, Jinlian
    Wang, Yifei
    Shao, Rong
    Xie, Jinping
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (06) : 1400 - 1407
  • [43] International regulations governing safety pharmacology, impact on drug development and regulatory dossiers
    Olejniczak, K
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2004, 197 (03) : 141 - 142
  • [44] A role for fMRI in optimizing CNS drug development
    Borsook, D
    Becerra, L
    Hargreaves, R
    NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (05) : 411 - 424
  • [45] A role for fMRI in optimizing CNS drug development
    David Borsook
    Lino Becerra
    Richard Hargreaves
    Nature Reviews Drug Discovery, 2006, 5 : 411 - 425
  • [46] Challenges in CNS drug development and the role of imaging
    Howes, Oliver D.
    Mehta, Mitul A.
    PSYCHOPHARMACOLOGY, 2021, 238 (05) : 1229 - 1230
  • [47] Targeted to neuronal organelles for CNS drug development
    Ying, Zheng
    Ye, Na
    Ma, Qilian
    Chen, Fan
    Li, Ningning
    Zhen, Xuechu
    ADVANCED DRUG DELIVERY REVIEWS, 2023, 200
  • [48] New Era for Novel CNS Drug Development
    Potter, William Z.
    NEUROPSYCHOPHARMACOLOGY, 2012, 37 (01) : 278 - 280
  • [49] CART Peptides as Targets for CNS Drug Development
    Hunter, Richard G.
    Kuhar, Michael J.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2003, 2 (03) : 201 - 205
  • [50] New Era for Novel CNS Drug Development
    William Z Potter
    Neuropsychopharmacology, 2012, 37 : 278 - 280
12345